Challenges and promises for planning future clinical research into bacteriophage therapy against Pseudomonas aeruginosa in cystic fibrosis. An argumentative review

Frontiers in Microbiology

Volumn 9, Issue MAY, 2018, Pages

  Rossitto, Martina ^a   Fiscarelli, Ersilia V ^a   Rosati, Paola ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

Author keywords

Bacteriophage therapy; Biofilm; Cystic fibrosis; Efficiency of plating; Lytic phages; Multidrug resistant Pseudomonas aeruginosa; Phage cocktails; Phages and antibiotics combined

Indexed keywords

ANTIBIOTIC AGENT; COLISTIN; TOBRAMYCIN;

ANTIBACTERIAL ACTIVITY; BACTERIAL GROWTH; BACTERIAL STRAIN; BIOFILM; CRISPR CAS SYSTEM; CROSS RESISTANCE; CYSTIC FIBROSIS; DRUG EFFICACY; DRUG SAFETY; GALLERIA MELLONELLA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHAGE THERAPY; PSEUDOMONAS AERUGINOSA; REVIEW;

EID: 85046653709     PISSN: None     EISSN: 1664302X     Source Type: Journal    
DOI: 10.3389/fmicb.2018.00775     Document Type: Review

References (157)

1. Abedon, S. T. (2017a). Information phage therapy research should report. Pharmaceuticals 10:43. doi: 10.3390/ph10020043
2. Abedon, S. T. (2017b). Phage Name Check. Available online at: http://www.phage.org/phage_name_check.html
3. Abedon, S. T., and Yin, J. (2009). Bacteriophage plaques: theory and analysis. Methods Mol. Biol. 501, 161-174. doi: 10.1007/978-1-60327-164-6_17
4. Ackermann, H. W. (1998). Tailed bacteriophages. The order Caudovirales. Adv. Virus Res. 51, 135-201. doi: 10.1016/S0065-3527(08)60785-X
5. Ackermann, H. W. (2005). "Bacteriophage classification," in Bacteriophages: Biology and Applications, eds E. Kutter, and A. Sulakvelidze (Boca Raton, FL: CRC Press), 169-187
6. Ackermann, H. W. (2011). Bacteriophage taxonomy. Microbiol. Aust. 32, 90-94
7. Adriaenssens, E., and Brister, J. R. (2017). How to name and classify your phage: an informal guide. Viruses 9:70. doi: 10.3390/v9040070
8. Alemayehu, D., Casey, P. G., McAuliffe, O., Guinane, C. M., Martin, J. G., Shanahan, F., et al. (2012). Bacteriophages FMR299-2 and FNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells. MBio 3:e00029-12. doi: 10.1128/mBio.00029-12
9. Alves, D. R., Perez-Esteban, P., Kot, W., Bean, J., Arnot, T., Hansen, L., et al. (2015). A novel bacteriophage cocktail reduces and disperses Pseudomonas aeruginosa biofilms under static and flow conditions. Microb. Biotechnol. 9, 61-74. doi: 10.1111/1751-7915.12316
10. American type culture collection [ATCC®] Available at: https://www.lgcstandards-atcc.org/
11. Anderson, G. G. (2012). "Pseudomonas aeruginosa biofilm formation in the CF lung and its implications for therapy," in Cystic Fibrosis-Renewed Hopes Through Research, ed D. Sriramulu (London: InTech), 153-180
12. Azeredo, J., and Sutherland, I. W. (2008). The use of phages for the removal of infectious biofilms. Curr. Pharm. Biotechnol. 9, 261-266. doi: 10.2174/138920108785161604
13. Bacci, G., Paganin, P., Lopez, L., Vanni, C., Dalmastri, C., Cantale, C., et al. (2016). Pyrosequencing unveils cystic fibrosis lung microbiome differences associated with a severe lung function decline. PLoS ONE 11:e0156807. doi: 10.1371/journal.pone.0156807
14. Barr, J. J., Auro, R., Furlan, M., Whiteson, K. L., Erb, M. L., Pogliano, J., et al. (2013). Bacteriophage adhering to mucus provide a non-host-derived immunity. Proc. Natl. Acad. Sci. U.S.A. 110, 10771-10776. doi: 10.1073/pnas.1305923110
15. Bassetti, M., Ginocchio, F., and Mikulska, M. (2011). New treatment options against gram-negative organisms. Crit. Care 15, 215. doi: 10.1007/978-3-642-18081-1_46
16. Battán, P. C., Barnes, A. I., and Albesa, I. (2004). Resistance to oxidative stress caused by ceftazidime and piperacillin in a biofilm of Pseudomonas. Luminescence 19, 265-270. doi: 10.1002/bio.779
17. Beeton, M. L., Alves, D. R., Enright, M. C., and Jenkins, A. T. (2015). Assessing phage therapy against Pseudomonas aeruginosa using a Galleria mellonella infection model. Int. J. Antimicrob. Agents 46, 196-200. doi: 10.1016/j.ijantimicag.2015.04.005
18. Betts, A., Vasse, M., Kaltz, O., and Hochberg, M. E. (2013). Back to the future: evolving bacteriophages to increase their effectiveness against the pathogen Pseudomonas aeruginosa PAO1. Evol. Appl. 6, 1054-1063. doi: 10.1111/eva.12085
19. Biswas, B., Adhya, S., Washart, P., Paul, B., Trostel, A. N., Powell, B., et al. (2002). Bacteriophage therapy rescues mice bacteremic from a clinical isolate of vancomycin-resistant Enterococcus faecium. Infect. Immun. 70, 204-210. doi: 10.1128/IAI.70.1.204-210.2002
20. Boles, B. R., Thoendel, M., and Singh, P. K. (2004). Self-generated diversity produces insurance effects in biofilm communities. Proc. Natl. Acad. Sci. U.S.A. 101, 16630-16635. doi: 10.1073/pnas.0407460101
21. Bondy-Denomy, J., Pawluk, A., Maxwell, K. L., and Davidson, A. R. (2013). Bacteriophages genes that inactivate the CRISPR/Cas bacterial immune system. Nature 493, 429-432. doi: 10.1038/nature11723
22. Bradley, D. E., and Robertson, D. (1968).The structure and infective process of a contractile Pseudomonas aeruginosa bacteriophage. J. Gen. Virol. 3, 247-254. doi: 10.1099/0022-1317-3-2-247
23. Brüssow, H. (2012). What is needed for phage therapy to become a reality in western medicine? Virology 434, 138-142. doi: 10.1016/j.virol.2012.09.015
24. Cady, K. C., Bondy-Denomy, J., Heussler, G. E., Davidson, A. R., and O'Toole, G. A. (2012). The CRISPR/Cas adaptive immune system of Pseudomonas aeruginosa mediates resistance to naturally occurring and engineered phages. J. Bacteriol. 194, 5728-5738. doi: 10.1128/JB.01184-12
25. Caplan, A. (2015). Morals, microbes, and methods. Lancet 385, e45. doi: 10.1016/S0140-6736(15)60928-X
26. Carmody, L. A., Gill, J. J., Summer, E. J., Sajjan, U. S., Gonzalez, C. F., Young, R. F., et al. (2010). Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J. Infect. Dis. 201, 264-271. doi: 10.1086/649227
27. Carrigy, N. B., Chang, R. Y., Leung, S. S., Harrison, M., Petrova, Z., Pope, W. H., et al. (2017). Anti-tuberculosis bacteriophage D29 delivery with a vibrating mesh nebulizer, jet nebulizer, and soft mist inhaler. Pharm. Res. 34, 2084-2096. doi: 10.1007/s11095-017-2213-4
28. Chan, B. K., and Abedon, S. T. (2012). Phage therapy pharmacology: phage cocktails. Adv. Appl. Microbiol. 78, 1-23. doi: 10.1016/B978-0-12-394805-2.00001-4
29. Chan, B. K., Abedon, S. T., and Loc-Carrillo, C. (2013). Phage cocktails and the future of phage therapy. Future Microbiol. 8, 769-783. doi: 10.2217/fmb.13.47
30. Chan, B. K., Sistrom, M., Wertz, J. E., Kortright, K. E., Narayan, D., and Turner, P. E. (2016). Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa. Sci. Rep. 6:26717. doi: 10.1038/srep26717
31. Chang, R. Y. K., Chen, K., Wang, J., Wallin, M., Britton, W., Morales, S., et al. (2017). Anti-pseudomonal activity of phage PEV20 in a dry powder formulation. A proof-of-principle study in a murine lung infection model. Antimicrob. Agents Chemother. 62:e01714-17. doi: 10.1128/AAC.01714-17
32. Chaturongakul, S., and Ounjai, P. (2014). Phage-host interplay: examples from tailed phages and gram-negative bacterial pathogens. Front. Microbiol. 5:442. doi: 10.3389/fmicb.2014.00442
33. Chaudhry, W. N., Concepción-Acevedo, J., Park, T., Andleeb, S., Bull, J. J., and Levin, B. R. (2017). Synergy and order effects of antibiotics and phages in killing Pseudomonas aeruginosa biofilms. PLoS ONE 12:e0168615. doi: 10.1371/journal.pone.0168615
34. Chmiel, J. F., and Davis, P. B. (2003). State of the art: why do the lungs of patients with cystic fibrosis become infected and why can't they clear the infection? Respir. Res. 4:8. doi: 10.1186/1465-9921-4-8
35. Clokie, M. R., Millard, A. D., Letarov, A. V., and Heaphy, S. (2011). Phages in nature. Bacteriophage 1, 31-45. doi: 10.4161/bact.1.1.14942
36. Cochran, W., Suh, S. J., McFeters, G., and Stewart, P. (2000). Role of RpoS and AlgT in Pseudomonas aeruginosa biofilm resistance to hydrogen peroxide and monochloramine. J. Appl. Microbiol. 88, 546-553. doi: 10.1046/j.1365-2672.2000.00995.x
37. Costerton, J. W., Stewart, P. S., and Greenberg, E. P. (1999). Bacterial biofilms: a common cause of persistent infections. Science 284, 1318-1322. doi: 10.1126/science.284.5418.1318
38. Costerton, W., Veeh, R., Shirtliff, M., Pasmore, M., Post, C., and Ehrlich, G. (2003). The application of biofilm science to the study and control of chronic bacterial infections. J. Clin. Invest. 112, 1466-1477. doi: 10.1172/JCI200320365
39. Coulter, L. B., McLean, R. J., Rohde, R. E., and Aron, G. M. (2014). Effect of bacteriophage infection in combination with tobramycin on the emergence of resistance in Escherichia coli and Pseudomonas aeruginosa biofilms. Viruses 6, 3778-3786. doi: 10.3390/v6103778
40. Criscuolo, E., Spadini, S., Lamanna, J., Ferro, M., and Burioni, R. (2017). Bacteriophages and their immunological applications against infectious threats. J. Immunol. Res. 2017:3780697. doi: 10.1155/2017/3780697
41. D'Hérelle, F. (1917). Sur un microbe invisible antagoniste des bacilles dysentériques. C R Acad. Sci. Ser. D. 165, 373-375
42. Danis-Wlodarczyk, K., Olszak, T., Arabski, M., Wasik, S., Majkowska-Skrobek, G., Augustyniak, D., et al. (2015). Characterization of the newly isolated lytic bacteriophages KTN6 and KT28 and their efficacy against Pseudomonas aeruginosa biofilm. PLoS ONE 10:e0137015. doi: 10.1371/journal.pone.0137015
43. Danis-Wlodarczyk, K., Vandenheuvel, D., Jang, H. B., Briers, Y., Olszak, T., Arabski, M., et al. (2016). A proposed integrated approach for the preclinical evaluation of phage therapy in Pseudomonas infections. Sci. Rep. 6:28115. doi: 10.1038/srep28115
44. Darch, S. E., Kragh, K. N., Abbott, E. A., Bjarnsholt, T., Bull, J. J., and Whiteley, M. (2017). Phage inhibit pathogen dissemination by targeting bacterial migrants in a chronic infection model. mBio 8, e00240-17. doi: 10.1128/mBio.00240-17
45. Davies, K. J., Lloyd, D., and Boddy, L. (1989). The effect of oxygen on denitrification in paracoccus denitrificans and Pseudomonas aeruginosa. J. Gen. Microbiol. 135, 2445-2451. doi: 10.1099/00221287-135-9-2445
46. Debarbieux, L., Leduc, D., Maura, D., Morello, E., Criscuolo, A., Grossi, O., et al. (2010). Bacteriophages can treat and prevent Pseudomonas aeruginosa lung infections. J. Infect. Dis. 201, 1096-1104. doi: 10.1086/651135
47. Deligianni, E., Pattison, S., Berrar, D., Ternan, N. G., Haylock, R. W., Moore, J. E., et al. (2010). Pseudomonas aeruginosa cystic fibrosis isolates of similar RAPD genotype exhibit diversity in biofilm forming ability in vitro. BMC Microbiol. 10:38. doi: 10.1186/1471-2180-10-38
48. Domingo-Calap, P., Georgel, P., and Bahram, S. (2016). Back to the future: bacteriophages as promising therapeutic tools. HLA 87, 133-140. doi: 10.1111/tan.12742
49. Donlan, R. M., and Costerton, J. W. (2002). Biofilms: survival mechanisms of clinically relevant microorganisms. Clin. Microbiol. Rev. 15, 167-193. doi: 10.1128/CMR.15.2.167-193.2002
50. Drulis-Kawa, Z., Majkowska-Skrobek, G., Maciejewska, B., Delattre, A. S., and Lavigne, R. (2012). Learning from bacteriophages-advantages and limitations of phage and phage-encoded protein applications. Curr. Protein. Pept. Sci. 13, 699-722. doi: 10.2174/138920312804871193
51. Edgar, R., Friedman, N., Molshanski-Mor, S., and Qimron, U. (2012). Reversing bacterial resistance to antibiotics by phage-mediated delivery of dominant sensitive genes. Appl. Environ. Microbiol. 78, 744-751. doi: 10.1128/AEM.05741-11
52. Escobar-Páramo, P., Gougat-Barbera, C., and Hochberg, M. E. (2012). Evolutionary dynamics of separate and combined exposure of Pseudomonas fluorescens SBW25 to antibiotics and bacteriophage. Evol. Appl. 5, 583-592. doi: 10.1111/j.1752-4571.2012.00248.x
53. Essoh, C., Blouin, Y., Loukou, G., Cablanmian, A., Lathro, S., Kutter, E., et al. (2013). The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages. PLoS ONE 8:e60575. doi: 10.1371/journal.pone.0060575
54. European molecular biology laboratory-European bioinformatics institute (EMBL-EBI). Available online at: https://www.ebi.ac.uk/
55. Frederiksen, B., Koch, C., and Høiby, N. (1997). Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic fibrosis. Pediatr. Pulmonol. 23, 330-335. doi: 10.1002/(SICI)1099-0496(199705)23:5<330::AID-PPUL4>3.0.CO;2-O
56. Friman, V. P., Soanes-Brown, D., Sierocinski, P., Molin, S., Johansen, H. K., Merabishvili, M., et al. (2016). Pre-adapting parasitic phages to a pathogen leads to increased pathogen clearance and lowered resistance evolution with Pseudomonas aeruginosa cystic fibrosis bacterial isolates. J. Evol. Biol. 29, 188-198. doi: 10.1111/jeb.12774
57. Furukawa, S., Kuchma, S., and O'Toole, G. (2006). Keeping their options open: acute versus persistent infections. J. Bacteriol. 188, 1211-1217
58. Garbe, J., Wesche, A., Bunk, B., Kazmierczak, M., Selezska, K., Rohde, C., et al. (2010). Characterization of JG024, a Pseudomonas aeruginosa PB1-like broad host range phage under simulated infection conditions. BMC Microbiol. 10:301. doi: 10.1186/1471-2180-10-301
59. Gellatly, S. L., and Hancock, R. E. (2013). Pseudomonas aeruginosa: new insights into pathogenesis and host defenses. Pathog. Dis. 67, 159-173. doi: 10.1111/2049-632X.12033
60. GenBank. Available online at: https://www.ncbi.nlm.nih.gov/genbank/
61. Gibson, R. L., Burns, J. L., and Ramsey, B. W. (2003). Pathophysiology and management of pulmonary infections in cystic fibrosis. Am. J. Respir. Crit. Care Med. 168, 918-951. doi: 10.1164/rccm.200304-505SO
62. Golshahi, L., Lynch, K. H., Dennis, J. J., and Finlay, W. H. (2011). In vitro lung delivery of bacteriophages KS4-M and FKZ using dry powder inhalers for treatment of Burkholderia cepacia complex and Pseudomonas aeruginosa infections in cystic fibrosis. J. Appl. Microbiol. 110, 106-117. doi: 10.1111/j.1365-2672.2010.04863.x
63. Gómez, M. I., and Prince, A. (2007). Opportunistic infections in lung disease: Pseudomonas infections in cystic fibrosis. Curr. Opin. Pharmacol. 7, 244-251. doi: 10.1016/j.coph.2006.12.005
64. Gooderham, W. J., and Hancock, R. E. (2009). Regulation of virulence and antibiotic resistance by two-component regulatory systems in Pseudomonas aeruginosa. FEMS Microbiol. Rev. 33, 279-294. doi: 10.1111/j.1574-6976.2008.00135.x
65. Hall, A. R., De Vos, D., Friman, V. P., Pirnay, J. P., and Buckling, A. (2012). Effects of sequential and simultaneous applications of bacteriophages on populations of Pseudomonas aeruginosa in vitro and in wax moth larvae. Appl. Environ. Microbiol. 78, 5646-5652. doi: 10.1128/AEM.00757-12
66. Hanlon, G. W., Denyer, S. P., Olliff, C. J., and Ibrahim, L. J. (2001). Reduction in exopolysaccharide viscosity as an aid to bacteriophage penetration through Pseudomonas aeruginosa biofilms. Appl. Environ. Microbiol. 67, 2746-2753. doi: 10.1128/AEM.67.6.2746-2753.2001
67. Harper, D. R., Parracho, H. M., Walker, J., Sharp, R., Hughes, G., Werthén, M., et al. (2014). Bacteriophages and biofilms. Antibiotics 3, 270-284. doi: 10.3390/antibiotics3030270
68. Henry, K. A., Arbabi-Ghahroudi, M., and Scott, J. K. (2015). Beyond phage display: non-traditional applications of the filamentous bacteriophage as a vaccine carrier, therapeutic biologic, and bioconjugation scaffold. Front. Microbiol. 6:755. doi: 10.3389/fmicb.2015.00755
69. Henry, M., Lavigne, R., and Debarbieux, L. (2013). Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections. Antimicrob. Agents Chemother. 57, 5961-5968. doi: 10.1128/AAC.01596-13
70. Himmelweit, F. (1945). Combined action of penicillin and bacteriophage on Staphylococci. Lancet 246, 104-105. doi: 10.1016/S0140-6736(45)91422-X
71. Høiby, N., Ciofu, O., and Bjarnsholt, T. (2010). Pseudomonas aeruginosa biofilms in cystic fibrosis. Future Microbiol. 5, 1663-1674. doi: 10.2217/fmb.10.125
72. Hraiech, S., Brégeon, F., and Rolain, J. M. (2015). Bacteriophage-based therapy in cystic fibrosis-associated Pseudomonas aeruginosa infections: rationale and current status. Drug Des. Devel. Ther. 9, 3653-3663. doi: 10.2147/DDDT.S53123
73. Hurley, M. N., Cámara, M., and Smyth, A. R. (2012). Novel approaches to the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. Eur. Respir. J. 40, 1014-1023. doi: 10.1183/09031936.00042012
74. Jassim, S. A., and Limoges, R. G. (2014). Natural solution to antibiotic resistance: bacteriophages "The Living Drugs". World J. Microbiol. Biotechnol. 30, 2153-2170. doi: 10.1007/s11274-014-1655-7
75. Jesaitis, A. J., Franklin, M. J., Berglund, D., Sasaki, M., Lord, C. I., Bleazard, J. B., et al. (2003). Compromised host defense on Pseudomonas aeruginosa biofilms: characterization of neutrophil and biofilm interactions. J. Immunol. 171, 4329-4339. doi: 10.4049/jimmunol.171.8.4329
76. Kaur, T., Nafissi, N., Wasfi, O., Sheldon, K., Wettig, S., and Slavcev, R. (2012). Immunocompatibility of bacteriophages as nanomedicines. J. Nanotech. 2012:247427. doi: 10.1155/2012/247427
77. Kimmelman, J., and Federico, C. (2017). Consider drug efficacy before first-in-human trials. Nature 542, 25-27. doi: 10.1038/542025a
78. Krylov, V. (2014), "Bacteriophages of Pseudomonas aeruginosa: long-term prospects for use in phage therapy," in Advances in Virus Research, Vol. 88, eds K. Maramorosch and F. A. Murphy (Oxford, UK: Elsevier), 227-278
79. Krylov, V., Shaburova, O., Pleteneva, E., Bourkaltseva, M., Krylov, S., Kaplan, A., et al. (2016). Modular approach to select bacteriophages targeting Pseudomonas aeruginosa for their application to children suffering with cystic fibrosis. Front. Microbiol. 7:1631. doi: 10.3389/fmicb.2016.01631
80. Kutateladze, M., and Adamia, R. (2010). Bacteriophages as potential new therapeutics to replace or supplement antibiotics. Trends Biotechnol. 28, 591-595. doi: 10.1016/j.tibtech.2010.08.001
81. Labrie, S. J., Samson, J. E., and Moineau, S. (2010). Bacteriophage resistance mechanisms. Nat. Rev. Microbiol. 8, 317-327. doi: 10.1038/nrmicro2315
82. Larché, J., Pouillot, F., Essoh, C., Libisch, B., Straut, M., Lee, J. C., et al. (2012). Rapid identification of international multidrug-resistant Pseudomonas aeruginosa clones by multiple-locus variable number of tandem repeats analysis and investigation of their susceptibility to lytic bacteriophages. Antimicrob. Agents Chemother. 56, 6175-6180. doi: 10.1128/AAC.01233-12
83. Lavelle, G. M., White, M. M., Browne, N., McElvaney, N. G., and Reeves, E. P. (2016). Animal models of cystic fibrosis pathology: phenotypic parallels and divergences. Biomed. Res. Int. 2016:5258727. doi: 10.1155/2016/5258727
84. Lehman, S., Branston, S., Smrekar, F., Pabary, R., Alton, E., Davies, J., et al. (2016). Bacteriophage therapy for the treatment of P. aeruginosa infections in cystic fibrosis patients. Available online at: http://investor.ampliphibio.com/sites/ampliphibio.investorhq.businesswire.com/files/event/additional/ECCMID_2016_POSTER_FINAL.pdf
85. Li, Z., Kosorok, M. R., Farrell, P. M., Laxova, A., West, S. E., Green, C. G., et al. (2005). Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis. JAMA 293, 581-588. doi: 10.1001/jama.293.5.581
86. Lim, W. S., Phang, K. K., Tan, A. H. M., Li, S. F. Y., and Ow, D. S. W. (2016). Small colony variants and single nucleotide variations in Pf1 region of PB1 phage-resistant Pseudomonas aeruginosa. Front. Microbiol. 7:282. doi: 10.3389/fmicb.2016.00282
87. Lin, D. M., Koskella, B., and Lin, H. C. (2017). Phage therapy: an alternative to antibiotics in the age of multi-drug resistance. World J. Gastrointest. Pharmacol. Ther. 8, 162-173. doi: 10.4292/wjgpt.v8.i3.162
88. Loc-Carrillo, C., and Abedon, S. T. (2011). Pros and cons of phage therapy. Bacteriophage 1, 111-114. doi: 10.4161/bact.1.2.14590
89. Lu, T. K., and Collins, J. J. (2007). Dispersing biofilms with engineered enzymatic bacteriophage. Proc. Natl. Acad. Sci. U.S.A. 104, 11197-11202. doi: 10.1073/pnas.0704624104
90. Mah, T. F., and O'Toole, G. A. (2001). Mechanisms of biofilm resistance to antimicrobial agents. Trends Microbiol. 9, 34-39. doi: 10.1016/S0966-842X(00)01913-2
91. Martis, N., Leroy, S., and Blanc, V. (2014). Colistin in multi-drug resistant Pseudomonas aeruginosa blood-stream infections: a narrative review for the clinician. J. Infect. 69, 1-12. doi: 10.1016/j.jinf.2014.03.001
92. Matinkhoo, S., Lynch, K. H., Dennis, J. J., Finlay, W. H., and Vehring, R. (2011). Spray-dried respirable powders containing bacteriophages for the treatment of pulmonary infections. J. Pharm. Sci. 100, 5197-5205. doi: 10.1002/jps.22715
93. Mattila, S., Ruotsalainen, P., and Jalasvuori, M. (2015). On-demand isolation of bacteriophages against drug-resistant bacteria for personalized phage therapy. Front. Microbiol. 6:1271. doi: 10.3389/fmicb.2015.01271
94. Mendes, J. J., Leandro, C., Mottola, C., Barbosa, R., Silva, F. A., Oliveira, M., et al. (2014). In vitro design of a novel lytic bacteriophage cocktail with therapeutic potential against organisms causing diabetic foot infections. J. Med. Microbiol. 63, 1055-1065. doi: 10.1099/jmm.0.071753-0
95. Merril, C. R., Scholl, D., and Adhya, S. L. (2003). The prospect for bacteriophage therapy in Western medicine. Nat. Rev. Drug Discov. 2, 489-497. doi: 10.1038/nrd1111
96. Middelboe, M. (2000). Bacterial growth rate and marine virus-host dynamics. Microb. Ecol. 40, 114-124. doi: 10.1007/s002480000050
97. Mirzaei, M. K., and Nilsson, A. S. (2015). Isolation of phages for phage therapy: a comparison of spot tests and efficiency of plating analyses for determination of host range and efficacy. PLoS ONE 10:e0118557. doi: 10.1371/journal.pone.0118557
98. Moreau-Marquis, S., Stantona, B. A., and OToole, G. A. (2008). Pseudomonas aeruginosa biofilm formation in the cystic fibrosis airway. a short review. Pulm. Pharmacol. Ther. 21, 595-599. doi: 10.1016/j.pupt.2007.12.001
99. Morello, E., Saussereau, E., Maura, D., Huerre, M., Touqui, L., and Debarbieux, L. (2011). Pulmonary bacteriophage therapy on Pseudomonas aeruginosa cystic fibrosis strains: first steps towards treatment and prevention. PLoS ONE 6:e16963. doi: 10.1371/journal.pone.0016963
100. Moretti, S., Renga, G., Oikonomou, V., Galosi, C., Pariano, M., Iannitti, R. G., et al. (2017). A mast cell-ILC2-Th9 pathway promotes lung inflammation in cystic fibrosis. Nat. Commun. 8:14017. doi: 10.1038/ncomms14017
101. Moskowitz, S. M., Foster, J. M., Emerson, J., and Burns, J. L. (2004). Clinically feasible biofilm susceptibility assay for isolates of Pseudomonas aeruginosa from patients with cystic fibrosis. J. Clin. Microbiol. 42, 1915-1922. doi: 10.1128/JCM.42.5.1915-1922.2004
102. Mumford, R., and Friman, V. P. (2017). Bacterial competition and quorum-sensing signalling shape the eco-evolutionary outcomes of model in vitro phage therapy. Evol. Appl. 10, 161-169. doi: 10.1111/eva.12435
103. Murray, T. S., Egan, M., and Kazmierczak, B. I. (2007). Pseudomonas aeruginosa chronic colonization in cystic fibrosis patients. Curr. Opin. Pediatr. 19, 83-88. doi: 10.1097/MOP.0b013e3280123a5d
104. Nadithe, V., Rahamatalla, M., Finlay, W. H., Mercer, J. R., and Samuel, J. (2003). Evaluation of nose-only aerosol inhalation chamber and comparison of experimental results with mathematical simulation of aerosol deposition in mouse lungs. J. Pharm. Sci. 92, 1066-1076. doi: 10.1002/jps.10379
105. Nouraldin, A. A. M., Baddour, M. M., Harfoush, R. A. H., and Essa, S. A. M. (2016). Bacteriophage-antibiotic synergism to control planktonic and biofilm producing clinical isolates of Pseudomonas aeruginosa. Alexandria Med. J. 52, 99-105. doi: 10.1016/j.ajme.2015.05.002
106. Olszak, T., Zarnowiec, P., Kaca, W., Danis-Wlodarczyk, K., Augustyniak, D., Drevinek, P., et al. (2015). In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients. Appl. Microbiol. Biotechnol. 99, 6021-6033. doi: 10.1007/s00253-015-6492-6
107. Pabary, R., Singh, C., Morales, S., Bush, A., Alshafi, K., Bilton, D., et al. (2016). Anti-pseudomonal bacteriophage reduces infective burden and inflammatory response in murine lung. Antimicrob. Agents Chemother. 60, 744-751. doi: 10.1128/AAC.01426-15
108. Parks, Q. M., Young, R. L., Poch, K. R., Malcolm, K. C., Vasil, M. L., and Nick, J. A. (2009). Neutrophil enhancement of Pseudomonas aeruginosa biofilm development: human F-actin and DNA as targets for therapy. J. Med. Microbiol. 58, 492-502. doi: 10.1099/jmm.0.005728-0
109. Parracho, H. M., Burrowes, B. H., Enright, M. C., McConville, M. L., and Harper, D. R. (2012). The role of regulated clinical trials in the development of bacteriophage therapeutics. J. Mol. Genet. Med. 6, 279-286. doi: 10.4172/1747-0862.1000050
110. Pei, R., and Lamas-Samanamud, G. R. (2014). Inhibition of biofilm formation by T7 bacteriophages producing quorum-quenching enzymes. Appl. Environ. Microbiol. 80, 5340-5348. doi: 10.1128/AEM.01434-14
111. Pires, D. P., Boas, D. V., Sillankorva, S., and Azeredo, J. (2015). Phage therapy: a step forward in the treatment of Pseudomonas aeruginosa infections. J. Virol. 89, 7449-7456. doi: 10.1128/JVI.00385-15
112. Pires, D. P., Cleto, S., Sillankorva, S., Azeredo, J., and Lu, T. K. (2016a). Genetically engineered phages: a review of advances over the last decade. Microbiol. Mol. Biol. Rev. 80, 523-543. doi: 10.1128/MMBR.00069-15
113. Pires, D. P., Oliveira, H., Melo, L. D., Sillankorva, S., and Azeredo, J. (2016b). Bacteriophage-encoded depolymerases: their diversity and biotechnological applications. Appl. Microbiol. Biotechnol. 100, 2141-2151. doi: 10.1007/s00253-015-7247-0
114. Pires, D., Sillankorva, S., Faustino, A., and Azeredo, J. (2011). Use of newly isolated phages for control of Pseudomonas aeruginosa PAO1 and ATCC 10145 biofilms. Res. Microbiol. 162, 798-806. doi: 10.1016/j.resmic.2011.06.010
115. Pirnay, J. P., De Vos, D., Verbeken, G., Merabishvili, M., Chanishvili, N., Vaneechoutte, M., et al. (2011). The phage therapy paradigm: pret-a-porter or sur-mesure? Pharm. Res. 28, 934-937. doi: 10.1007/s11095-010-0313-5
116. Pirnay, J. P., Verbeken, G., Rose, T., Jennes, S., Zizi, M., Huys, I., et al. (2012). Introducing yesterday's phage therapy in today's medicine. Future Virol. 7, 379-390. doi: 10.2217/fvl.12.24
117. Pollini, S., Fiscarelli, E., Mugnaioli, C., Di Pilato, V., Ricciotti, G., Neri, A. S., et al. (2011). Pseudomonas aeruginosa Infection in cystic fibrosis caused by an epidemic metallo-β-lactamase-producing clone with an heterogeneous carbapenem resistance phenotype. Clin. Microbiol. Infect. 17, 1272-1275. doi: 10.1111/j.1469-0691.2011.03466.x
118. Rasamiravaka, T., Labtani, Q., Duez, P., and El Jaziri, M. (2015). The formation of biofilms by Pseudomonas aeruginosa: a review of the natural and synthetic compounds interfering with control mechanisms. Biomed. Res. Int. 2015, 17. doi: 10.1155/2015/759348
119. Reardon, S. (2014). Phage therapy gets revitalized. Nature 510, 15-16. doi: 10.1038/510015a
120. Riou, M., Carbonnelle, S., Avrain, L., Mesaros, N., Pirnay, J. P., Bilocq, F., et al. (2010). In vivo development of antimicrobial resistance in Pseudomonas aeruginosa strains isolated from the lower respiratory tract of intensive care unit patients with nosocomial pneumonia and receiving antipseudomonal therapy. Int. J. Antimicrob. Agents 36, 513-522. doi: 10.1016/j.ijantimicag.2010.08.005
121. Rogers, G. B., Carroll, M. P., Serisier, D. J., Hockey, P. M., Kehagia, V., Jones, G. R., et al. (2005). Bacterial activity in cystic fibrosis lung infections. Respir. Res. 6:49. doi: 10.1186/1465-9921-6-49
122. Ryan, E. M., Gorman, S. P., Donnelly, R. F., and Gilmore, B. F. (2011). Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. J. Pharm. Pharmacol. 63, 1253-1264. doi: 10.1111/j.2042-7158.2011.01324.x
123. Sahota, J. S., Smith, C. M., Radhakrishnan, P., Winstanley, C., Goderdzishvili, M., Chanishvili, N., et al. (2015). Bacteriophage delivery by nebulization and efficacy against phenotypically diverse Pseudomonas aeruginosa from cystic fibrosis patients. J. Aerosol. Med. Pulm. Drug Deliv. 28, 353-360. doi: 10.1089/jamp.2014.1172
124. Saiman, L., Siegel, J. D., LiPuma, J. J., Brown, R. F., Bryson, E. A., Chambers, M. J., et al. (2014). Infection prevention and control guideline for cystic fibrosis: 2013 update. Infect. Control Hosp. Epidemiol. 35, S1-S67. doi: 10.1086/676882
125. Salmond, G. P., and Fineran, P. C. (2015). A century of the phage: past, present and future. Nat. Rev. Microbiol. 13, 777-786. doi: 10.1038/nrmicro3564
126. Sarhan, W. A., and Azzazy, H. M. E. (2015). Phage approved in food not as a therapeutic? Expert Rev. Anti Infect. Ther. 13, 91-101. doi: 10.1586/14787210.2015.990383
127. Saussereau, E., Vachier, I., Chiron, R., Godbert, B., Sermet, I., Dufour, N., et al. (2014). Effectiveness of bacteriophages in the sputum of cystic fibrosis patients. Clin. Microbiol. Infect. 20, O983-O990. doi: 10.1111/1469-0691.12712
128. Schopf, J. W. (1992). "The oldest fossils and what they mean, "in Major Events in the History of Life, ed J. W. Schopf (Boston, MA: Jones and Bartlett), 29-63
129. Shabalova, L. A., Kapranov, N. I., Krylov, V. N., Sharibjanova, T. O., and Akhverdian, V. Z. (1995). "Pseudomonas aeruginosa bacteriophage in treatment of P. aeruginosa infection in cystic fibrosis patients," in Proceedings of IX International Cystic Fibrosis Congress (Zurich: International Cystic Fibrosis Association), 443
130. Shen, K., Sayeed, S., Antalis, P., Gladitz, J., Ahmed, A., Dice, B., et al. (2006). Extensive genomic plasticity in Pseudomonas aeruginosa revealed by identification and distribution studies of novel genes among clinical isolates. Infect. Immun. 74, 5272-5283. doi: 10.1128/IAI.00546-06
131. Sievert, D. M., Ricks, P., Edwards, J. R., Schneider, A., Patel, J., Srinivasan, A., et al. (2013). Antimicrobial-resistant pathogens associated with healthcare-associated infections summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2009-2010. Infect. Control Hosp. Epidemiol. 34, 1-14. doi: 10.1086/668770
132. Sillankorva, S., Oliveira, R., Vieira, M. J., Sutherland, I., and Azeredo, J. (2004). Bacteriophage F S1 infection of Pseudomonas fluorescens planktonic cells versus biofilms. Biofouling 20, 133-138. doi: 10.1080/08927010410001723834
133. Smith, E. E., Buckley, D. G., Wu, Z., Saenphimmachak, C., Hoffman, L. R., D'Argenio, D. A., et al. (2006). Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients. Proc. Natl. Acad. Sci. U.S.A. 103, 8487-8492. doi: 10.1073/pnas.0602138103
134. Smith, G. P. (1985). Filamentous fusion phage: novel expression vectors that display cloned antigens on the vision surface. Science 228, 1315-1317. doi: 10.1126/science.4001944
135. Starkey, M., Hickman, J. H., Ma, L., Zhang, N., De Long, S., Hinz, A., et al. (2009). Pseudomonas aeruginosa rugose small-colony variants have adaptations that likely promote persistence in the cystic fibrosis lung. J. Bacteriol. 191, 3492-3503. doi: 10.1128/JB.00119-09
136. Stuart, B., Lin, J. H., and Mogayzel, P. J. (2010). Early eradication of Pseudomonas aeruginosa in patients with cystic fibrosis. Paediatr. Respir. Rev. 11, 177-184. doi: 10.1016/j.prrv.2010.05.003
137. Sulakvelidze, A., Alavidze, Z., and Morris, J. G. (2001). Bacteriophage therapy. Antimicrob. Agents Chemother. 45, 649-659. doi: 10.1128/AAC.45.3.649-659.2001
138. Theuretzbacher, U. (2009). Future antibiotics scenarios: is the tide starting to turn? Int. J. Antimicrob Agents 34, 15-20. doi: 10.1016/j.ijantimicag.2009.02.005
139. Thiel, K. (2004). Old dogma, new tricks 21st century phage therapy. Nat. Biotechnol. 22, 31-36. doi: 10.1038/nbt0104-31
140. Tiwari, B. R., Kim, S., Rahman, M., and Kim, J. (2011). Antibacterial efficacy of lytic Pseudomonas bacteriophage in normal and neutropenic mice models. J. Microbiol. 49, 994-999. doi: 10.1007/s12275-011-1512-4
141. Torres-Barceló, C., Arias-Sánchez, F. I., Vasse, M., Ramsayer, J., Kaltz, O., and Hochberg, M. E. (2014). A window of opportunity to control the bacterial pathogen Pseudomonas aeruginosa combining antibiotics and phages. PLoS ONE 9:e106628. doi: 10.1371/journal.pone.0106628
142. Torres-Barceló, C., and Hochberg, M. E. (2016). Evolutionary rationale for phages as complements of antibiotics. Trends Microbiol. 24, 249-256. doi: 10.1016/j.tim.2015.12.011
143. Trend, S., Fonceca, A. M., Ditcham, W. G., and Kicic, A. (2017). The potential of phage therapy in cystic fibrosis: Essential human-bacterial-phage interactions and delivery considerations for use in Pseudomonas aeruginosa-infected airways. J. Cyst. Fibros. 16,663-670. doi: 10.1016/j.jcf.2017.06.012
144. Twort, F. W. (1915). An investigation on the nature of ultra-microscopic viruses. Lancet 186, 1241-1243. doi: 10.1016/S0140-6736(01)20383-3
145. Uchiyama, J., Suzuki, M., Nishifuji, K., Kato, S.-I., Miyata, R., Nasukawa, T., et al. (2016). Analyses of short-term antagonistic evolution between Pseudomonas aeruginosa strain PAO1 and phage KPP22 belonging to the family Myoviridae genus PB1-like viruses. Appl. Environ. Microbiol. 82, 4482-4491. doi: 10.1128/AEM.00090-16
146. Verbeken, G., De Vos, D., Vaneechoutte, M., Merabishvili, M., Zizi, M., and Pirnay, J. P. (2007). European regulatory conundrum of phage therapy. Future Microbiol. 2, 485-491. doi: 10.2217/17460913.2.5.485
147. Waddell, T. E., Franklin, K., Mazzocco, A., Kropinski, A. M., and Johnson, R. P. (2009). "Generalized transduction by lytic bacteriophages," in Bacteriophages: Methods and Protocols, Vol. 1. Isolation, Characterization, and Interactions, eds M. R. J. Clokie and A. M. Kropinski (Hertfordshire: Humana Press), 293-303
148. Walker, T. S., Tomlin, K. L., Worthen, G. S., Poch, K. R., Lieber, J. G., Saavedra, M. T., et al. (2005). Enhanced Pseudomonas aeruginosa biofilm development mediated by human neutrophils. Infect. Immun. 73, 3693-3701. doi: 10.1128/IAI.73.6.3693-3701.2005
149. Walters, M. C., Roe, F., Bugnicourt, A., Franklin, M. J., and Stewart, P. S. (2003). Contributions of antibiotic penetration, oxygen limitation, and low metabolic activity to tolerance of Pseudomonas aeruginosa biofilms to ciprofloxacin and tobramycin. Antimicrob. Agents Chemother. 47, 317-323. doi: 10.1128/AAC.47.1.317-323.2003
150. Wang, J., Hu, B., Xu, M., Yan, Q., Liu, S., Zhu, X., et al. (2006). Use of bacteriophage in the treatment of experimental animal bacteremia from imipenem-resistant Pseudomonas aeruginosa. Int. J. Mol. Med. 17, 309-317. doi: 10.3892/ijmm.17.2.309
151. Waters, E. M., Neill, D. R., Kaman, B., Sahota, J. S., Clokie, M. R., Winstanley, C., et al. (2017). Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa. Thorax 72, 666-667. doi: 10.1136/thoraxjnl-2016-209265
152. Weber-Dabrowska, B., Jonczyk-Matysiak, E., Zaczek, M., Lobocka, M., Lusiak-Szelachowska, M., and Górski, A. (2016). Bacteriophage procurement for therapeutic purposes. Front. Microbiol. 7:1177. doi: 10.3389/fmicb.2016.01177
153. Wei, Q., and Ma, L. Z. (2013). Biofilm matrix and its regulation in Pseudomonas aeruginosa. Int. J. Mol. Sci. 14, 20983-21005. doi: 10.3390/ijms141020983
154. Winstanley, C., O'Brien, S., and Brockhurst, M. A. (2016). Pseudomonas aeruginosa evolutionary adaptation and diversification in cystic fibrosis chronic lung infections. Trends Microbiol. 24, 327-337. doi: 10.1016/j.tim.2016.01.008
155. Wright, A., Hawkins, C., Anggård, E., and Harper, D. (2009). A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin. Otolaryngol. 34, 349-357. doi: 10.1111/j.1749-4486.2009.01973.x
156. Xu, K. D., McFeters, G. A., and Stewart, P. S. (2000). Biofilm resistance to antimicrobial agents. Microbiology 146, 547-549. doi: 10.1099/00221287-146-3-547
157. Yoon, S. S., and Hassett, D. J. (2004). Chronic Pseudomonas aeruginosa infection in cystic fibrosis airway disease: metabolic changes that unravel novel drug targets. Expert Rev. Anti Infect. Ther. 2, 611-623. doi: 10.1586/14787210.2.4.611